| Abstract |
Abstract: Objective: To explore the effect of using amisulpiride combined with aripiprazole in the treatment of schizophrenia patients and its impact on cognitive function and short-term memory function. Method: From May 2021 to May 2023, 112 patients with schizophrenia who visited our hospital were selected as the study subjects and divided into groups using a random number table method. 56 cases in the control group were treated with sulfamethoxazole, while 56 cases in the experimental group were treated with aripiprazole. After 8 weeks of treatment, compare the clinical efficacy, severity of mental disorders, cognitive function, short-term memory function, and adverse reactions between the two groups of patients. Result: The total effective rate of the experimental group was higher than that of the control group (P<0.05); The scores of general psychopathological symptoms, negative symptoms, and positive symptoms in the experimental group were lower than those in the control group (P<0.05); The scores of immediate memory, visual spatial structure, language, attention, and delayed memory in the experimental group were higher than those in the control group (P<0.05); The experimental group had higher scores in images, recognition, memorization, and association than the control group (P<0.05); Comparison of adverse reaction rates between two groups (P>0.05). Conclusion: The combination of amisulpiride and aripiprazole can effectively alleviate clinical symptoms, improve cognitive function and short-term memory function, enhance treatment efficacy, and have high safety in patients with schizophrenia.
|